$MRK (-2,12%) and $MRNA (+3,98%)
announced landmark positive topline results from their Phase 3 INTerpath-001 clinical trial. This represents the first successful Phase 3 trial for a personalized, mRNA-based cancer vaccine in medical history.
Core Announcement Details
- The Treatment: An individualized neoantigen therapy (INT) named intismeran (V940/mRNA-4157) combined with Merck’s standard immunotherapy, Keytruda
Trial Milestones: The combination regimen successfully hit its primary endpoint of recurrence-free survival (RFS)and a key secondary endpoint of distant metastasis-free survival (DMFS
key financials of the operation
cancer vaccine (intismeran/V940) collaboration features a 50/50 split of development costs and future profits, with Merck having paid a $250 million upfront fee. Analysts project the therapy could reach $16.8 billion in global sales by 2035, with initial melanoma treatment costs expected to mirror high-end immunotherapies like Keytruda.
